Foghorn Therapeutics (NASDAQ: FHTX) net income
Foghorn Therapeutics reported a net loss of $74.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $86.6m. Earnings per share were −$1.18.
Foghorn Therapeutics's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$74.3m | — | −240.3% | −$1.18 |
| 2024 | −$86.6m | — | −383.2% | −$1.58 |
| 2023 | −$98.4m | — | −288.2% | −$2.34 |
| 2022 | −$108.9m | — | −566.3% | −$2.62 |
| 2021 | −$101.3m | — | −7,681.6% | −$2.73 |
| 2020 | −$68.8m | — | −16,000.0% | −$6.23 |
| 2019 | −$51.1m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Foghorn Therapeutics net income compared with its sector
By net income for its latest fiscal year, Foghorn Therapeutics ranks 302nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Foghorn Therapeutics, −240.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 300th | Beta Bionics | −$73.2m | −73.0% |
| 301st | Tectonic Therapeutic | −$74.2m | — |
| 302nd | Foghorn Therapeutics | −$74.3m | −240.3% |
| 303rd | MacroGenics | −$74.6m | −49.9% |
| 304th | Fulcrum Therapeutics | −$74.9m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Foghorn Therapeutics
- How much did Foghorn Therapeutics earn in fiscal 2025?
- Foghorn Therapeutics reported a net loss of $74.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $86.6m.
- What are the earnings per share of Foghorn Therapeutics?
- They were −$1.18 in fiscal 2025, compared with −$1.58 in fiscal 2024.
- Where does Foghorn Therapeutics rank in its sector by net income?
- It ranks 302nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Foghorn Therapeutics come from?
- From the annual report (Form 10-K) that Foghorn Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Foghorn Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Foghorn Therapeutics: the Foghorn Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.